Shanghai HUTCHMED Investment (HK) Limited, commonly referred to as HUTCHMED, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, the company has rapidly established itself in the global healthcare landscape, focusing on the development and commercialisation of innovative cancer therapies and immunotherapies. With a strong operational presence in both China and the United States, HUTCHMED is dedicated to addressing unmet medical needs through its unique portfolio of targeted therapies. The company’s flagship products, including innovative small molecules and monoclonal antibodies, are designed to improve patient outcomes in oncology. HUTCHMED has achieved significant milestones, including successful clinical trials and strategic partnerships, positioning itself as a leader in the biopharmaceutical industry. Its commitment to research and development, combined with a robust pipeline, underscores its role as a key player in advancing cancer treatment solutions.
We don't have data for Shanghai HUTCHMED Investment (HK) Limited, but we can show you information about their parent organization instead.
View parent company